Clinical Trials
62 trialsMK-3475-587
Merck Sharp & Dohme LLC
MonumenTAL-1
Janssen Research & Development, LLC
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Janssen Research & Development, LLC
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
Kyowa Kirin Co., Ltd.
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
MK-1026-003
Merck Sharp & Dohme LLC
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Daiichi Sankyo
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
APEX
Cogent Biosciences, Inc.
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
DALY 2-EU
Miltenyi Biomedicine GmbH
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Pulmotect, Inc.
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Swedish Orphan Biovitrum
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
QUATRO-APL
Quetzal Therapeutics
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Immunome, Inc.
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
ADAPT-HEM
Beijing Biotech
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Aquarius
Tempus AI
SPI-FOL-102
Acrotech Biopharma Inc.
Hesperia
Lakefront Biotherapeutics NV
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
Nanjing RegeneCore Biotech Co., Ltd.
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
Hemanext
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
Grit Biotechnology
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Incyte Corporation
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Beijing InnoCare Pharma Tech Co., Ltd.
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
Hutchmed
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Grit Biotechnology
The Study of ICP-248 in Patients With Mature B-cell Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Century Therapeutics, Inc.
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Hangzhou Weben Pharma Co., Ltd
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Servier
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Pack Health
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
CARCML
Hikma Pharmaceuticals LLC
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Onward Therapeutics
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Shenzhen TargetRx Co., Ltd.
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Hangzhou DAC Biotechnology Co., Ltd.
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
BELUGA
Munich Leukemia Laboratory